In conclusion, our study provides a first pre-clinical validation of the hypothesis that targeting GHR can improve anti-cancer therapeutic success in vivo for two different human cancers associated with marked drug resistance and high lethality – melanoma and hepatocellular carcinoma. This evidence concerns the gene GHR and hepatocellular carcinoma.